Profile data is unavailable for this security.
About the company
Shuttle Pharmaceuticals Holdings, Inc. is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Its product candidates include Ropidoxuridine, a Phase II, clinical-stage radiation sensitizer, a platform of HDAC inhibitors (SP-1-161, SP-2-225 and SP-1-303), and two preclinical, prostate cancer-oriented diagnostics assets: PC-RAD Test, a blood test to predict clinical response to radiation therapy and PSMA-B ligand for potential use as a theranostic agent. Ropidoxuridine (IPdR) is for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. SP-1-161 is a candidate lead of compounds demonstrating activation of the ATM gene product (mutated in Ataxia-Telangiectasia). SP-2-225 is a candidate lead of compounds demonstrating Class II (HDAC6) selective inhibition. SP-1-303 is a candidate Class I HDAC inhibitor with preferential efficacy against ER positive cancers.
- Revenue in USD (TTM)0.00
- Net income in USD-10.71m
- Incorporated2018
- Employees9.00
- LocationShuttle Pharmaceuticals Holdings Inc401 Professional Drive, Suite 260GAITHERSBURG 20879United StatesUSA
- Phone+1 (240) 403-4212
- Fax+1 (845) 818-3588
- Websitehttps://shuttlepharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioRestorative Therapies Inc | 383.40k | -12.67m | 2.58m | 11.00 | -- | 1.04 | -- | 6.72 | -1.48 | -1.48 | 0.0447 | 0.2766 | 0.0379 | -- | 4.30 | 34,854.55 | -125.35 | -149.02 | -207.73 | -188.71 | 93.34 | -- | -3,304.77 | -11,837.37 | -- | -- | 0.00 | -- | 175.03 | 25.27 | 13.81 | -- | 24.41 | -- |
| Oragenics Inc | 0.00 | -10.90m | 2.74m | 3.00 | -- | 0.2756 | -- | -- | -17.15 | -17.15 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -121.78 | -113.47 | -168.95 | -126.49 | -- | -- | -- | -34,218.60 | -- | -14.92 | 0.0386 | -- | -100.00 | -- | 48.84 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -63.41m | 2.85m | 1.00 | -- | 0.1976 | -- | -- | -45.47 | -45.47 | 0.00 | 1.08 | 0.00 | -- | -- | 0.00 | -702.98 | -- | -1,223.40 | -- | -- | -- | -- | -- | -- | -56.99 | 0.0422 | -- | -- | -- | -2,826.43 | -- | -- | -- |
| Enzolytics Inc | 0.00 | -119.19k | 2.90m | 2.00 | -- | -- | -- | -- | -0.106 | -0.106 | 0.00 | -1.04 | 0.00 | -- | -- | -- | -369.52 | -- | -- | -- | -- | -- | -- | -- | -- | -4.30 | -- | -- | -100.00 | -- | -9.35 | -- | -- | -- |
| Geovax Labs Inc | 3.35m | -25.31m | 2.91m | 17.00 | -- | 0.4068 | -- | 0.8677 | -49.15 | -49.15 | 5.86 | 4.13 | 0.3759 | -- | 12.25 | 197,268.20 | -283.68 | -128.86 | -377.44 | -172.81 | -- | -- | -754.69 | -1,385.19 | -- | -- | 0.00 | -- | -- | 27.45 | 3.75 | -- | 22.10 | -- |
| Enveric Biosciences Inc | 0.00 | -11.25m | 2.92m | 5.00 | -- | 0.1326 | -- | -- | -94.63 | -94.63 | 0.00 | 15.83 | 0.00 | -- | -- | 0.00 | -212.68 | -146.94 | -262.78 | -198.90 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.16 | -- | -- | -- |
| Shuttle Pharmaceuticals Holdings Inc | 0.00 | -10.71m | 2.98m | 9.00 | -- | 0.9837 | -- | -- | -25.86 | -25.86 | 0.00 | 1.13 | 0.00 | -- | -- | 0.00 | -507.78 | -- | -3,614.50 | -- | -- | -- | -- | -- | -- | -- | 0.2305 | -- | -- | -- | -38.71 | -- | -- | -- |
| Dermata Therapeutics Inc | 0.00 | -8.85m | 3.08m | 8.00 | -- | 0.2751 | -- | -- | -28.37 | -28.37 | 0.00 | 4.69 | 0.00 | -- | -- | 0.00 | -150.49 | -136.32 | -203.36 | -201.56 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -57.64 | -- | -- | -- |
| Psyence Biomedical Ltd | -100.00bn | -100.00bn | 3.16m | 12.00 | -- | 0.0125 | -- | -- | -- | -- | -- | 247.64 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 101.98 | -- | -- | -- |
| Adial Pharmaceuticals Inc | 0.00 | -8.05m | 3.17m | 5.00 | -- | 0.6032 | -- | -- | -23.22 | -23.22 | 0.00 | 4.72 | 0.00 | -- | -- | 0.00 | -130.16 | -205.76 | -155.01 | -274.10 | -- | -- | -- | -- | -- | -27.38 | 0.00 | -- | -- | -- | -88.48 | -- | -- | -- |
| ProtoKinetix, Inc. | 0.00 | -376.18k | 3.21m | 0.00 | -- | 12.77 | -- | -- | -0.001 | -0.001 | 0.00 | 0.0006 | 0.00 | -- | -- | -- | -78.62 | -530.88 | -117.20 | -607.05 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.34 | -- | 18.34 | -- |
| GRI Bio Inc | 0.00 | -11.96m | 3.34m | 4.00 | -- | 0.1914 | -- | -- | -248.19 | -248.19 | 0.00 | 12.07 | 0.00 | -- | -- | 0.00 | -166.00 | -190.54 | -236.14 | -330.83 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.17 | -- | 8.45 | -- |
| Vaccinex Inc | 601.00k | -18.63m | 3.35m | 23.00 | -- | -- | -- | 5.57 | -9.91 | -9.91 | 0.2864 | -0.9295 | 0.193 | -- | 0.6682 | 26,130.44 | -598.49 | -299.11 | -- | -- | -- | -- | -3,100.50 | -3,700.14 | -- | -149.88 | -- | -- | 5.44 | 2.82 | 7.98 | -- | -22.36 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Connective Capital Management LLCas of 30 Sep 2025 | 100.54k | 21.79% |
| Geode Capital Management LLCas of 31 Dec 2025 | 14.44k | 3.13% |
| UBS Switzerland AG (Investment Management)as of 31 Dec 2025 | 9.25k | 2.00% |
| UBS Securities LLCas of 31 Dec 2025 | 2.70k | 0.59% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.02k | 0.22% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 27.00 | 0.01% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 8.00 | 0.00% |
| Desjardins Securities, Inc.as of 31 Dec 2025 | 2.00 | 0.00% |
| Citigroup Global Markets, Inc. (Investment Management)as of 31 Dec 2025 | 1.00 | 0.00% |
| DRW Securities LLCas of 31 Dec 2025 | 0.00 | 0.00% |
